What Researchers Did
Researchers reported on a single patient with mucormycosis, liver cirrhosis, and diabetes who was successfully treated with antifungal agents, surgery, and hyperbaric oxygen therapy.
What They Found
The patient, who suffered from maxillary sinusitis and osteomyelitis, was successfully treated with liposomal amphotericin B, itraconazole, posaconazole, surgical debridement, and hyperbaric oxygen therapy. Despite having liver cirrhosis (Child-Pugh classification B), the patient did not develop hepatic decompensation during posaconazole treatment. This was noted as the first report of posaconazole being safely and effectively used for mucormycosis in a cirrhotic patient.
What This Means for Canadian Patients
For Canadian patients with mucormycosis, especially those with underlying conditions like liver cirrhosis and diabetes, this case suggests that a comprehensive approach involving antifungal medications, surgery, and hyperbaric oxygen therapy could be an effective treatment strategy. The successful and safe use of posaconazole in a cirrhotic patient offers a potential treatment option for similar complex cases without causing liver complications.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a single case report, these findings cannot be broadly applied to all patients with mucormycosis and liver cirrhosis.